share_log

T2 Biosystems | 4: Statement of changes in beneficial ownership of securities-Officer Giffin Brett A.

SEC announcement ·  Feb 21 05:06
Summary by Futu AI
Brett A. Giffin, the Chief Commercial Officer of T2 Biosystems, Inc. (TTOO), executed a transaction on February 20, 2024, involving the acquisition of 13 shares of common stock. The transaction was classified as an exercise or conversion of derivative security, as per the transaction code 'M'. Following this transaction, Giffin's direct holdings in the company increased to a total of 77 shares of common stock. The transaction reflects a continued investment by the executive in the company, signaling confidence in T2 Biosystems' prospects.
Brett A. Giffin, the Chief Commercial Officer of T2 Biosystems, Inc. (TTOO), executed a transaction on February 20, 2024, involving the acquisition of 13 shares of common stock. The transaction was classified as an exercise or conversion of derivative security, as per the transaction code 'M'. Following this transaction, Giffin's direct holdings in the company increased to a total of 77 shares of common stock. The transaction reflects a continued investment by the executive in the company, signaling confidence in T2 Biosystems' prospects.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.